NMN is one of the most-Googled longevity supplements on earth — and one of the most over-promised. Here's every human trial that actually exists, the one distinction that decides everything, and an honest grade. No affiliate links.
I wanted NMN to work. The story is seductive: a molecule your body already makes, declining as you age, that you can simply top back up. So I did what I do — I stopped reading the headlines and read the actual human trials. Here's the honest picture.
This is the deep-dive companion to our 22-supplement scorecard, where NMN earned a C. This page is why.
NMN (nicotinamide mononucleotide) is a building block your body uses to make NAD+, a molecule every cell needs to turn food into energy and run its repair machinery. Here's the seductive part: NAD+ levels fall as we age. So the logic writes itself — top up the precursor, restore NAD+, and maybe slow the whole machine's decline.
That theory got rocket fuel from Harvard's David Sinclair and the broader sirtuin/NAD+ research world. It's genuinely interesting biology. But “interesting biology” and “works in humans” are two different bars — and the gap between them is where most longevity money quietly disappears.
The one distinction that decides everything on this page: raising NAD+ is a mechanism. Living longer or healthier is an outcome. NMN clears the first bar easily. Whether it clears the second — in actual people — is the entire question, and the honest answer is: not shown.
There are now roughly a dozen randomized human trials of NMN. They cluster into two honest conclusions: yes, it raises NAD+, and it nudges scattered biomarkers in specific groups — with no two trials quite agreeing on which ones.
Yoshino et al., Science, 2021. A 10-week randomized trial in 25 prediabetic, overweight, postmenopausal women taking 250 mg/day. The headline: muscle insulin sensitivity improved by about 25%. The fine print: body weight, fat mass, blood pressure, blood glucose, and lipids did not change — and other scientists publicly questioned the result in a formal Comment in the same journal. A real signal, in a narrow group, hotly debated.
Aerobic capacity: a 2021 trial in 48 recreational runners found higher-dose NMN (600–1200 mg/day) improved aerobic-capacity markers over six weeks. Walking speed and sleep: a 2024 trial in healthy adults 65–75 reported that 250 mg/day for 12 weeks shortened a 4-metre walk time, raised NAD+, and improved self-reported sleep. Lipids: a 2023 trial in 36 healthy middle-aged adults reported small drops in LDL cholesterol, body weight, and diastolic blood pressure.
A 2024 systematic review of 10 randomized trials (about 437 participants, mean age 58, doses 150–1200 mg/day, averaging under 10 weeks) concluded NMN modestly improved some physical-performance measures. Note what that sentence does not say: nothing about lifespan, disease, or biological age — because no trial has measured those.
So the trials are real, and the news isn't all bad. But look at the shape of the evidence: small (often 20–50 people), short (weeks, not years), scattered (a different biomarker each time), and frequently industry-funded. That's the profile of an early, promising compound — not a proven one.
If you tried to buy NMN in 2023 and found it suddenly hard to get, here's why. The regulatory story is its own saga:
So NMN is legal again in the US as of late 2025 — but notice what that whole drama was about: shelf legality, not whether it works. A supplement can be perfectly legal and still unproven. Those are different questions, and the marketing loves to blur them.
NMN sits in the honest middle. It's not snake oil — it's a real molecule with real human trials and a plausible mechanism, and it appears safe in the short term. But it's nowhere near the “reverse aging” product it's sold as. It moves biomarkers; it has never been shown to move the thing you actually care about.
What this means for you: If you're spending real money on NMN expecting to age more slowly, the evidence doesn't back that yet — you're funding a hypothesis. If you're an early adopter who finds the biomarker signals interesting and the short-term safety reassuring, that's a defensible personal experiment at a modest dose. Just buy third-party-tested, and don't let it crowd out the things that did earn an A or B: strength training, protein, sleep, and fixing real deficiencies.
Our anti-aging guide collects every intervention that survives real human research — what to do, how much, and the studies behind each one, with zero supplement hype.
See the Full GuideNo human study shows that. Trials show NMN raises NAD+ and, in specific groups, nudges biomarkers like insulin sensitivity or walking speed. Those are surrogate measures, not proof of slower aging, and the trials are small and short. Raising NAD+ is the hoped-for mechanism, not a demonstrated outcome.
Yes, in the US as of late 2025. The FDA excluded NMN from the supplement definition in 2022, then reversed course in September 2025 and formally reinstated it as a lawful dietary ingredient in December 2025, after a petition and lawsuit. It's still a New Dietary Ingredient, so manufacturers face premarket notification rules.
Both are NAD+ precursors with the same core limitation: they reliably raise NAD+ without proof of a real-world anti-aging payoff in healthy people. NR has somewhat more human trials; NMN has the famous insulin-sensitivity result. Neither has earned more than a C. If you're choosing between them for longevity, you're choosing between two unproven options.
In short trials at up to ~900–1200 mg/day it's been well tolerated with no serious adverse effects reported. But "no problems in a 12-week study of a few dozen people" is not the same as "proven safe for years," and label accuracy varies a lot between brands. Buy third-party-tested and tell your doctor.
— Scott Covert, 60, skeptic, not a physician. I wanted NMN to work, then read the trials. Think I read one wrong, or have a study I missed? Tell me and I'll dig in.